A Study of SKB518 in Patients With Lung Cancer

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Trial Details

NCT ID
NCT07019675
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SKB518
  • Tislelizumab
  • Carboplatin
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Nanning, Guangxi, China|22.81667,108.31667
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Wuhan, Hubei, China|30.58333,114.26667
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Age between 18 and 75 years old at the time of signing the informed consent form, applicable to both males and females.
  • Non-small cell lung cancer (NSCLC) or small cell lung cancer(SCLC) confirmed by histology or cytology.
  • At least one measurable tumor lesion per RECIST v1.1.
  • Performance status score of 0-1 according to the Eastern Cooperative Oncology Group (ECOG) scale.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →